Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.

NCT00681187 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00681187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00681187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, International, Open-label, Randomised, Cross-over Study to Assess Patient Preference and Health Economy in Patients With Neuroendocrine Tumours, Treated With Lanreotide Autogel Given as Self Administration.
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2008
Completion date
August 31, 2010
Enrollment
26 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

neuroendocrine tumour with carcinoid symptoms